Skip to main content
Industry News
FDA grants orphan drug status to remdesivir for COVID-19

The FDA approved Gilead's request to grant orphan drug status to remdesivir, an antiviral that is being tested in people with COVID-19, the disease caused by the novel coronavirus. Orphan drugs that are approved get breaks on taxes and fees and get seven years' market exclusivity.

Full Story: